Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TL-895 + Ruxolitinib in Myelofibrosis
NCT05280509Phase 2Recruiting
- Sponsor
- Telios Pharma
- Start
- Jun 2022
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of TL-895 in myelofibrosis (MF) (5 arms), sponsored by Telios Pharma. Primary endpoints: Recommended Phase 2 Dose at 28 days and Spleen Volume Reduction at 24 weeks. Started Jun 2022; status: recruiting.
02
Drugs
TL-895
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05280509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05280509.